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Inflammatory effects of peritoneal dialysis: Evidence of systemic mono-
cyte activation. We evaluated in peritonitis-free patients undergoing
continuous ambulatory peritoneal dialysis (CAPD) the release of both
interleukin-6 (IL-6) and f3-2-microglobulin (J32m) by cultured peripheral
blood mononuclear cells (PBMC), as well as the levels of serum amyloid
A (SAA), that is, the main hepatic acute phase protein during inflamma-
tion. The same measurements were obtained in hemodialysis (HD)
patients, uremic non-dialyzed patients (ESRD) and healthy controls (CON).
In CAPD, IL-6 production from PBMC was markedly increased in compar-
ison to the control value (600.7 104.3 vs. 14.2 3.6 pg/3 X 106 PBMC/24
hr, P < 0.005). Similarly, a striking enhancement of the PBMC release of
132m was detected in CAPD with respect to CON (10.1 2.6 vs. 0.063
0.013 jg/3 >< 10' PBMC/24 hr, P < 0.001). Also, the SAA levels were
significantly greater in CAPD patients (21.3 8.7 rg/dl) than in controls
(3.14 0.17 j.rg/dl, P < 0.05). Analogous increases of both IL-6 and 2m
cell releases, as well as of SAA levels, were observed in HD patients. No
difference concerning the three parameters was detected between CON
and ESRD. In conclusion, CAPD inducesperse PBMC activation with an
enhanced release of both IL-6 and f32m; this is associated to higher levels
of SAA. These systemic inflammatory effects are comparable to those
observed in HD patients indicating that CAPD is similar to HD in terms
of biocompatibility of the treatment.
Poor biocompatibility is a relevant characteristic of hemodial-
ysis treatment (HD); it has been implicated in the pathophysiol-
ogy of some HD-induced acute symptoms such as fever, nausea,
headache and hypotension [1]. A long-term consequence of this
phenomenon is hemodialysis-related amyloidosis (HRA) [2, 3].
Indeed, the type of dialysis membrane used strongly influences
both the production of /3-2-microglobulin (/32m), which is the
main protein constituent of HRA deposits [4, 5], and the preva-
lence over time of the clinical signs of HRA [61. These effects have
been essentially attributed to systemic inflammatory events in
which activation of circulating monocytes with increased produc-
tion of cytokines appears to play a central role [7—11].
Until now the study of the biocompatibility of substitutive
treatments in uremic patients has focused mainly on the extracor-
poreal hemodialysis, while little information concerning perito-
neal dialysis has been provided. Nevertheless, this procedure is
believed to induce a local inflammatory response independently
from bacterial invasion [12—151. Furthermore, the presence of
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/32m-amyloidosis has also been shown in patients treated with
continous ambulatory peritoneal dialysis (CAPD) [16, 17]. These
findings are therefore consistent with the hypothesis that perito-
neal dialysis is poorly biocompatible as the extracorporeal treat-
ment.
Interestingly, we have recently demonstrated an enhanced
production of interleukin 6 (IL-6) by peripheral blood mononu-
clear cells (PBMC) harvested from HD patients treated with
cuprophan membrane [18]. This cytokine plays a relevant role in
the regulation of the hepatic acute phase protein response to
inflammation [19—21]; however, the potential relationship be-
tween IL-6 and acute phase proteins has not been evaluated in
either HD or CAPD patients. Furthermore, we showed in the
same study a strong relationship between IL-6 production, sec-
ondary to the blood interaction with cellulosic membrane, and
f32m synthesis [18]. High circulating levels of f32m have been
demonstrated in CAPD patients as well [16, 22]; however,
whether this is merely dependent to reduced renal catabolism!
excretion or, alternatively, to enhanced cell production as in HD
remains unclear.
The aim of the present study was to investigate the systemic
inflammatory effects of continuous peritoneal dialysis. According
to our previous protocol in HD [18], we evaluated the release of
both IL-6 and /32m by cultured PBMC obtained from CAPD
patients. The levels of serum amyloid A (SAA), the main hepatic
acute phase protein during inflammation [23, 24], were also
assessed. To gain insights into the specific effects of peritoneal
dialysis on these three inflammation markers, the same measure-
ments were compared with the data obtained from HD patients,
uremic nondialyzed patients and healthy controls.
Methods
Patient selection
We studied 24 patients with end-stage renal disease: 7 patients
were undialyzed and constituted the ESRD group, 8 patients were
on CAPD, and 9 were on HD (Table 1). Seven healthy laboratory
staff volunteers (3 males and 4 females, mean age 35.7 8.3
years) were included in the study as controls (CON). All subjects
gave an informed consent prior to the study.
Tables 2 and 3 list the main biochemical and renal character-
istics of ESRD, HD and CAPD patients. All CAPD patients were
daily treated with four exchanges of 2 liters of dialysate (1.36% to
3.86% glucose, Baxter, Italy). The HD procedure was regularly
performed three times a week (4 hr/session) with bicarbonate
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Table I. Clinical characteristics of patients with end-stage renal disease
not dialyzed (ESRD), undergoing continous ambulatory peritoneal
dialysis (CAPD) and in extracorporeal hemodialysis (HD)
ESRD CAPD HD
N 7 8 9
Male/female 4/3 4/4 5/4
Age years 57.2 7.3 58.5 7.3 53.2 12.7
Dialytic age months — 21.3 8.7 23.5 10.6
Primary renal disease
Chronic glomerulonephritis 4 3 4
Chronic pyelonephritis 1 1 —
Polycystic kidney disease 1 — 2
Obstructive uropathy — 2 1
Hypertension 1 2 2
Data are expressed as mean SEM.
dialysate and using cuprophan membranes (membrane surface
1.2 m2; sterilization with ethylene oxide; BelIco Italy).
None of the patients had clinical evidence of acute infection or
autoimmune disease, nor were they taking any drug interfering
with the immune response. No patient had diabetes mellitus.
CAPD patients were peritonitis-free during the last six months
prior to the study.
Kt/Vure was estimated in HD patients as follows [25]:
Kt/Vwea =
—ln(R[— 0.03) + (4 to 3.5 X R) X UFIW
Where R is the ratio of the post-dialysis to the pre-dialysis plasma
urea, UF is the ultrafiltration volume (L) during dialysis, and W is
the post-dialysis weight (kg). In CAPD patients, Kt/V was calcu-
lated from the product of the dialysate outflow during a 24 hours
period and average dialysate to plasma ratio of urea (D/Purca).
The volume of distribution (V) was considered equal to total body
water and was estimated from the Watson equation [261.
Cell cultures
In HD patients, blood samples were collected in the morning
before the second dialysis session of the week. The samples from
CAPD patients were drawn after the overnight exchange. Periph-
eral blood mononuclear cells (PBMC) were isolated and set up as
primary in vitro cultures as previously described [18, 271. Briefly, in
order to obtain PBMC from heparinized whole blood samples, we
used Ficoll-Hypaque (Flow Laboratories, Irvine, Scotland, UK)
gradient density centrifugation at 400 g for 30 minutes at room
temperature. The interphase layer was washed twice (at 300 g for
10 mm) with RPMI 1640 (Flow Laboratories); the cells were then
resuspended in 15 ml polypropylene round bottom tubes (Falcon)
at a concentration of 3 X 106/ml in the following culture media:
Iscove's medium (Flow Laboratories) supplemented with 1%
heat-inactivated fetal bovine serum (Sigma Chimica, Milan; Italy)
and antibiotics (100 U/mI penicillin and 100 rg/ml streptomycin,
Sigma). PBMC were cultured in either the absence or the presence
of 10 .tg/ml of lipopolysaccharide (LPS) of Neisseria meningitidis
(Sigma). The dosage of LPS was chosen on the basis of preliminar
work in our lab and previous studies by other groups that demon-
strated a maximal release of IL-6 under these conditions [10, 28].
After 24 hours of incubation at 37°C, in a humidified atmosphere
containing 5% C02, cell-free supernatants were collected by centrif-
ugation for 10 minutes at 400 g, passaged through a millipore filter
(0.2 j.t, Sigma), and stored at —20°C.
Table 2. Biochemical data of patients with end-stage renal disease not
dialyzed (ESRD), undergoing continous ambulatory peritoneal dialysis
(CAPD) and in extracorporeal hemodialysis (HD)
ESRD CAPD HD
Albumin g/di 3.6 0.5 3.6 0.3 3.8 0.2
Total protein g/dl 6.8 0.4 6.9 0.5 7.1 0.5
Cholesterol mg/dl 192 71 155 68 187 94
Creatinine mg/di 6.4 2.1 6.0 2.3 10.3 4.0
BUN mg/di 62.4 8.3 59.1 10.7 87.4 13.2
Data are expressed as mean SEM.
Table 3. GFR, urinary output and weekly Kt/V of patients with end-
stage renal disease not dialyzed (ESRD), undergoing continous
ambulatory peritoneal dialysis (CAPD) and in extracorporeal
hemodialysis (HD)
ESRD CAPD HD
GFR mi/mm 12.4 2.5 2.6 0.9 1.1 0.3
Urinary output mi/day 1130 260 280 195 90 85
Kt/V — 1.9 0.3 2.9 0.5
Data are expressed as mean SEM.
The relative number of PBMC was not different in the four
groups, being, on average, 35% of the white cells (33 to 38%).
PBMC contained 80% of lymphocytes and 20% of monocytes; the
percentage of monocytes was similar in the different groups. Cell
viability was determined by Trypan blue exclusion test and yielded
98% viable cells.
Assays
All the samples from the different groups of patients were
analyzed at the same time.
IL-6 immunoassay. IL-6 was measured in supernatants from
PBMC by a sandwich ELISA (Biokine, Cambridge, MA, USA) in
which a monoclonal antibody to human IL-6 was used, a lyophi-
lized horseradish peroxidase conjugated goat anti-mouse which
binds to the monoclonal portion of the sandwich. The lower
detection limit was 7 pg/ml. The coefficient of variation of intra-assay
was 5% and inter-assay was 9%.
132m assay. A commercially available FIA kit (Eurogenetic,
Tessenderlo, Belgium) was used to quantifr the /32m concentra-
tion in the culture supernatant. The sensitivity of this assay was
0.05 jsg/ml; the coefficient of variation of intra-assay was 3.8% and
inter-assay was 5.6%.
SAA assay. SAA concentration was measured by using an
enzyme-immunoassay method (Hemagen diagnostic, Waltham,
MA, USA), based on the disruption of noncovalent interactions
occurring between SAA and other plasma constituents and the
subsequent self-coating of microwells by SAA. A peroxidase-
conjugated rabbit-anti-human SAA which binds to SAA adsorbed
on wells, was used. The lower detection limit was 3 sg/mI; the
coefficient of variation of intra-assay was 4.1% and inter-assay was
6.8%.
Statistical analysis
Statistical analysis was performed using the analysis of variance
(ANOVA) and linear regression analysis. Data are expressed as
mean SEM; statistical significance was defined as P < 0.05.
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Fig. 1 Interleukin-6 (IL-6) production in 24-hr cultured peripheral blood
mononuclear cells (PBMC) harvested from control subjects (CON), and from
patients with end-stage renal disease not dialyzed (ESRD), undergoing
continous ambulatoiy peritoneal dialysis (CAPD), and in extracorporeal
hemodialysis (HD). IL-6 production in CAPD and HD is significantly
greater than in CON and ESRD (P < 0.01).
Results
PBMC production of IL-6
As depicted in Figure 1, IL-6 production from unstimulated
PBMC was significantly higher in CAPD patients (600.7 104.3
pgI3 >< 106 PBMC/24 hr) and HD patients (664.3 138.9 pgI3 X
106 PBMC/24 hr) than the value measured in both ESRD patients
(18.6 4.0 pg/3 X 106 PBMC/24 hr, P < 0.005) and healthy
controls (14.2 3.6 pg/3 X 106 PBMC/24 hr, P < 0.005). IL-6
production was analogous in HD and CAPD. Similarly, no
difference was detected between healthy subjects and ESRD
patients.
When PBMC collected from ESRD and CON were stimulated
by a 24-hour LPS incubation the production of IL-6 markedly
increased up to 1462.0 179.5 and 1446.3 142.8 pg/3 X 106
PBMC/24 hr, respectively (Fig. 2). In CAPD and HD, IL-6 release
after LPS stimulation was 1117.8 138.6 and 925.4 161.8 pg/3
>< 106 PBMC/24 hr, respectively. These values were significantly
lower than those observed in ESRD and CON (Fig. 2).
PBMC release of /32m
The release of 2m from unstimulated PBMC was markedly
increased in CAPD (10.1 1.6 j.rg/3 x 106 PBMC/24 hr) and HD
(12.7 2.3 jxg/3 >< 106 PBMC/24 hr) in comparison with data
obtained in healthy controls (0.063 0.010 xgI3 x l0 PBMC/24
hr, P < 0.001) and ESRD patients (0.16 0.03 jxg/3 X 106
PBMC/24 hr, P < 0.01; Fig. 3).
Fig. 2. Interleukin-6 (JL-6) production in 24-hr cultured peripheral blood
mononuclear cells (PBMC) stimulated by 10 p1/mI of LPS and harvested
from control subjects (CON), and in patients with end-stage renal disease not
dialyzed (ESRD), undergoing continous ambulatoiy peritoneal dialysis
(CAPD) and in extracorporeal hemodialysis (HD). *p < 0.05 versus CON
and ESRD; **p < 0.05 versus CON, ESRD and CAPD.
No difference was detected in the f32m release between CAPD
and HD, as well as between healthy subjects and ESRD patients.
Serum levels of SAA
The values of SAA were significantly greater in CAPD (21.3
9.7 xg/ml) and HD (34.1 14.8 xg!m1) than in ESRD (5.3 2.2
jig/mi, P < 0.05) and controls (3.14 0.17 jxg/ml, P < 0.05) (Fig.
4).
No significant difference was observed in the SAA values
between CAPD and HD, and between ESRD and CON.
Regression analysis
Highly significant linear correlations were obtained between
IL-6 and J32m synthesis (r = 0.805, P < 0.001), IL-6 and SAA
values (r = 0.691, P < 0.005), and between /32m release and SAA
levels (r = 0.815, P < 0.001).
Discussion
Peritoneal dialysis has long been considered more biocompat-
ible than HD; this assumption has been essentially based on the
absence of the main factors underlying the poor biocompatibility
of the extracorporeal circulation, such as the blood interaction
with artificial membranes and the back-filtration/diffusion of
endotoxin fragments from dialysate [29, 30]. Nevertheless, in the
last few years, different studies in CAPD patients have demon-
strated the presence of chronic sterile inflammation at the level of
the peritoneum [14]. Recent studies have evidenced significant
intraperitoneal levels of IL-6 generated by peritoneal macro-
phages and/or mesothelial cells in absence of peritonitis [31, 32].
Overall these data suggest local inflammatory effects strictly
dependent on the CAPD treatment per se.
The present study adds new important information on this
issue: we provide first-time evidence that regular peritoneal
dialysis induces systemic activation of monocytes in absence of
peritonitis or other apparent cause of inflammation.
Peripheral blood mononuclear cells harvested from CAPD
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Fig. 3. -2-microglobulin (132m) release in 24-hr cultured peripheral blood
mononuclear cells (PBMC) harvested from control subjects (CON), and in
patients with end-stage renal disease not dialyzed (ESRD), undergoing
continous amhulatoy peritoneal dialysis (GA PD) and in ext racorporeal
hemodialysis (HD). fl2m release in CAPD and HD is significantly greater
than in CON and ESRD (P < 0.01).
patients released higher amounts of IL-b than those obtained
from healthy controls. This inflammatory cytokine plays a relevant
role in the pathophysiology of the low hiocompatibility of the HD
treatment [11, 18]. Interestingly, in the current study, the amount
of IL-6 released by cultured PBMC from CAPD patients was
comparable to that detected in PBMC drawn from HD patients of
analogous dialytic age and treated with cuprophan membrane.
This observation suggests an analogous degree of activation of the
circulating monocytes in the two treatments.
Of note, as opposed to unstimulated conditions, the cell
production after the 24 hour incubation with LPS was lower in
CAPD and HD patients with respect to both ESRD and CON
groups (Fig. 2). This observation is consistent with the hypothesis
of a chronic monocyte activation in dialyzed patients. Indeed, the
reduced response to LPS in CAPD and HD was possibly depen-
dent on a down-regulation of IL-6 production due to the chronic
stimulation of these cells. Similar findings supporting this hypoth-
esis have been reported by our group [18] and recently by Zaoui
and Hakim as well [33].
As for IL-6 release, also the PBMC production of 7m was
markedly enhanced in CAPD to levels comparable to those
measured in patients undergoing extracorporeal dialysis. f32m can
be considered a marker of systemic inflammation. Indeed, an
augmented synthesis of this protein occurs in rheumatic disorders
and infectious diseases [34—36]; moreover, its release is stimulated
by both T and B cell antigens [37]. This process is regulated by
various inflammatory cytokines, such as tumor necrosis factor,
y-interferon and interleukin-2 [38—40]. On this regard, our and
other groups have previously demonstrated that PBMC cultured
from HD patients treated with cuprophan membranes produce,
proportionally to IL-6, more 132m than patients dialyzed with
biocompatible membranes [5, 18]. The highly significant linear
correlation between IL-6 and 2m production observed in the
current study further support these findings.
Previous studies have evidenced an increase of the serum levels
of 2m and various cytokines in HD and CAPD patients [11, 16,
22, 41]. In the current work the cell production of both IL-6 and
2m was similarly low in uremic non-dialyzed patients and healthy
controls. This finding does not suggest that the chronic activation
of peripheral monocytes is determined by the retention of uremic
solutes. Alternatively, it can be at least partially attributed to the
enhanced ccli generation induced by the dialytic treatment per Se.
The pathophysiological mechanisms underlying the activation
of systemic monocytes in our CAPD patients are not readily
apparent. While some authors believe that dialysis fluids used in
CAPD inhibit cytokine generation [42, 43], recent in vitro studies
have demonstrated that diethylexylphtalate, a "plasticizer" re-
leased by storage bags, induces cytokine release from PBMC cells
[44]. Moreover, Dinarello and Krueger have reported the pres-
ence in the peritoneal dialysis effluent of natural muramyl dipep-
tides derived from bacterial cell wall that are capable to activate
mononuclear cells with a potency tenfold greater than endotoxins
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Fig. 4. Semni levels of amyloid A (SAA) in control subjects (CON), and in
patients with end-stage renal disease not dialyzed (ESRD), undergoing
continous amhulato,y peritoneal dialysis (GAP!)) and in ext racoiporeal
hemodialysis (HD). Serum levels of SAA in CAPD and HD are signifi-
HD cantly greater than in CON and ESRD (P < 0.05).
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[45]. It is therefore conceivable to hypothesize that these cells may
have been stimulated upon the contact with some specific sub-
stances in the peritoneum. Another factor potentially contributing
to the induction of systemic monocytes is possibly represented by
the complement activation which has been reported in peritonitis-
free CAPD patients [46].
Interestingly, in both HD and CAPD groups, the increased
PBMC production of either IL-6 or /32m was paralleled by a
striking increment of serum amyloid A levels, that is, the main
acute phase protein secreted by hepatocytes during inflammation
[23, 241. The systemic concentration of SAA was significantly
higher than the value detected in the two control groups of uremic
non-dialyzed patients and healthy subjects, thus suggesting en-
hanced SAA production rather than reduced renal catabolism!
excretion. This finding therefore constitutes further evidence of a
systemic inflammatory response to the dialytic therapy which is
not influenced by the type of substitutive treatment adopted. SAA
production during inflammation is essentially induced by the
direct interaction of IL-6 with the hepatocytes [23]. Accordingly,
the strong linear correlation detected between IL-6 production by
PBMC and SAA levels indicates that IL-6 may be involved in the
increase of SAA levels in both HD and CAPD as well.
In conclusion, the present controlled study demonstrates that:
(a) CAPD patients free of peritonitis show a marked enhance-
ment of the PBMC release of IL-6 and j32m that is associated with
an increment in SAA levels; (b) comparable changes of these
inflammation markers are detected in HD patients; (c) conversely,
both the IL-6 and f32m cell production and the SAA levels result
similarly low in healthy and uremic non-dialyzed subjects. There-
fore, CAPD induces per se systemic inflammatory events similarly
as the extracorporeal treatment. These findings are consistent
with the concept that regular peritoneal dialysis may not be
different from hemodialysis in terms of biocompatibility.
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